545 related articles for article (PubMed ID: 20299363)
1. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
4. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
7. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
8. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
10. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
11. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
12. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
13. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
14. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
Schiller B; Besarab A
Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
[TBL] [Abstract][Full Text] [Related]
15. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
16. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
17. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
18. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
19. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
Dahl NV; Henry DH; Coyne DW
Semin Dial; 2008; 21(3):210-1. PubMed ID: 18397204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]